British Journal of Dermatology Accepted Articles Accepted, unedited articles published online and citable. The final edited and typeset Version of Record will appear in the future.

---

Original Articles

The cost of childhood atopic dermatitis in a multi‐ethnic Asian population: a cost‐of‐illness study

M. Olsson, R. Bajpai, L.W.Y. Wee, Y.W. Yew, M.J.A. Koh, S. Thng, J. Car, K. Järbrink

First Published: 17 August 2019

Research Letters

A novel NCSTN missense mutation in the signal peptide domain causes hidradenitis suppurativa, which has features characteristic of an autoinflammatory keratinization disease

T. Takeichi, T. Matsumoto, T. Nomura, M. Takeda, H. Niwa, M. Kono, H. Shimizu, T. Ogi, M. Akiyama

First Published: 17 August 2019

Original Articles

DLQI‐R scoring improves the discriminatory power of Dermatology Life Quality Index in psoriasis, pemphigus and morphea patients

F. Rencz, L. Gulácsi, M. Péntek, A. Szegedi, É.  Remenyik, Z. Bata‐Csörgő, G. Bali, B. Hidvégi, B. Tamási, A.K. Poór, K. Hajdu, P. Holló, Á. Kinyó, M. Sárdy, V. Brodszky

First Published: 16 August 2019

Research Letters

Developing an online patient education resource for topical therapy: a pilot study

T.J. Tull, K. Jackson, C.H. Smith, A.E. Pink

First Published: 16 August 2019

Research Letters

Effect of the lymphovascular plugging metastasis pattern in extramammary Paget disease on identifying metastatic lesions by imaging tests: An autopsy case series

T. Maeda, K. Yoshino, K. Nagai, S. Oaku, M. Kato, A. Hiura, J. Uehara, Y. Fujisawa

First Published: 16 August 2019

Research Letters

An Association between Hidradenitis Suppurativa and HIV

P.H. Deng, C.J. Wang, A.W. Armstrong

First Published: 13 August 2019

Original Articles

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

A. Wollenberg, L.A. Beck, A. Blauvelt, E.L. Simpson, Z. Chen, Q. Chen, B. Shumel, F.A. Khokhar, T. Hultsch, E. Rizova, A.B. Rossi, N.M.H. Graham, G. Pirozzi, Y. Lu, M. Ardeleanu

First Published: 13 August 2019

Original Articles

Genetic Alterations in Primary Melanoma in Taiwan

Y.‐S. Sheen, K.‐T. Tan, K.‐P. Tse, Y.‐H. Liao, M.‐H. Lin, J.‐S. Chen, J.‐Y. Liau, Y.‐J. Tseng, C.‐H. Lee, C.‐H. Hong, J.‐B. Liao, H.‐T. Chang, C.‐Y. Chu

First Published: 13 August 2019

British Journal of Dermatology Early View Online Version of Record before inclusion in an issue

---

Qualitative and Outcomes Research

A qualitative analysis of psychological distress in hidradenitis suppurativa

E. Keary, D. Hevey, A.M. Tobin

Version of Record online: 14 August 2019

What's already known about this topic?

• Hidradenitis suppurativa (HS) has been shown to be associated with physical pain, a higher risk of depression, difficulties in sustaining employment and difficulties in relationships.
• Additionally, studies using quality‐of‐life measures have found more impairment in HS than in other dermatological conditions.

What does this study add?

• Although the research to date has determined that there are negative social and emotional consequences associated with HS, the psychological processes underlying these impairments have not yet been looked at.
• This study aims to get a deeper understanding of the lived experience of psychological distress in HS and how individuals with HS attempt to manage this distress.

What are the clinical implications of the work?

• This study has identified shame as a key feature that underlies the psychological difficulties experienced as a consequence of HS.
• When deciding upon appropriate psychological interventions for HS, approaches that specifically focus on reducing feelings of shame should be considered.

Medical dermatology

Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change

N.M. Teske, H.T. Jacobe

Version of Record online: 14 August 2019

What's already known about this topic?

• The Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) is a clinical tool that separately quantifies disease activity and damage in morphoea, and prior studies have demonstrated validity and reliability.

What does this study add?

• The LoSCAT can be used to classify patients with morphoea by disease severity into mild, moderate and severe groups, and to identify clinically significant improvement in disease activity in patients with morphoea.
• The LoSCAT may be limited in its ability to detect clinically significant changes in disease damage.

Respond to this article

Letters to the Editor

The role of misclassification of exposure in the association between aspirin and nonsteroidal anti‐inflammatory drug use and keratinocyte cancers: reply from the authors

N. Pandeya, C.M. Olsen, D.C. Whiteman

Version of Record online: 13 August 2019

Image Correspondence

Image Gallery: A case of onychomatricoma with typical clinical, dermoscopic and histopathological findings

X.‐K. Zou, J. Yu, S.‐X. Yang

Version of Record online: 13 August 2019

Research Letters

The detection rate of human papillomavirus in well‐differentiated squamous cell carcinoma and keratoacanthoma: is there new evidence for a viral pathogenesis of keratoacanthoma?

C. Conforti, F. Paolini, A. Venuti, C. Dianzani, I. Zalaudek

Version of Record online: 13 August 2019

Research Letters

Women with moderate‐to‐severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age‐adjusted fertility rate when compared with the general population

A. Gonzalez‐Cantero, G. Carretero, R. Rivera, C. Ferrándiz, E. Daudén, P. de la Cueva, F.J. Gómez‐García, I. Belinchón, E. Herrera‐Ceballos, D. Ruiz‐Genao, M. Ferrán, M. Alsina, J.L. Sánchez‐Carazo, O. Baniandrés, A. Sahuquillo‐Torralba, L. Rodriguez, J. Vilar, C. García, J.M. Carrascosa, M. Llamas‐Velasco, E. Herrera‐Acosta, J.L. López‐Estebaranz, R. Botella‐Estrada, M.A. Descalzo, I. García‐Doval, the BIOBADADERM Study Group

Version of Record online: 13 August 2019

Commentary

Staphylococcus aureus and host interaction in the flare‐ups of hidradenitis suppurativa

E.J. Giamarellos‐Bourboulis

Version of Record online: 12 August 2019

Commentary

The pain of hidradenitis suppurativa: ‘We only see what we know’

R. Alhusayen

Version of Record online: 12 August 2019

Commentary

How I learned to stop worrying about antidrug antibodies

R. Gniadecki

Version of Record online: 12 August 2019

Commentary

MicroRNAs: one for all, all for one

V. Wally, J.W. Bauer

Version of Record online: 12 August 2019

Translational Research

Detection of cell‐free circulating BRAFV600E by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance

N. Calbet‐Llopart, M. Potrony, G. Tell‐Martí, C. Carrera, A. Barreiro, P. Aguilera, S. Podlipnik, S. Puig, J. Malvehy, J.A. Puig‐Butillé

Version of Record online: 12 August 2019

What's already known about this topic?

• The analysis of the BRAF c.1799T>A (p.V600E) mutation in cell‐free (cf)DNA has emerged as a potential biomarker for monitoring prognosis and treatment response in patients with metastatic BRAF^V600E melanoma.
• The BRAF^V600E alteration is a common genetic alteration found in benign proliferations such as melanocytic naevi.
• No information exists about the impact of the number of common acquired naevi or the presence of clinically atypical naevi in cfBRAF^V600Edetection in an individual.

What does this study add?

• The cfBRAF^V600E mutation is detected in plasma from a reduced number of individuals without melanoma undergoing continuous dermatological follow‐up.
• A high number of naevi or the presence of clinically atypical naevi are factors that do not influence cfBRAF^V600E detection in an individual.
• Both total cfBRAF concentration and cfBRAF^V600E frequency are effective biomarkers in patients with advanced melanoma but not in patients at early stages or with micrometastases.

What is the translational message?

• Detection of cfBRAF^V600E in an individual is not influenced by naevus‐related factors.
• cfBRAF^V600E is a robust and reliable biomarker that can be used in dermatological surveillance programmes.

Commentary

Paediatric discoid lupus erythematosus: importance of subspecialty collaboration

N. Ruth, L. Wine Lee

Version of Record online: 12 August 2019

Commentary

Microbiome, probiotics and dermatology

J.A. Cardenas‐de la Garza, W. Haidari, S.R. Feldman

Version of Record online: 12 August 2019